Myocardial infarction and its consequences such as congestive heart failure continue to be a major cause of death in Western societies despite therapeutic advances made in recent years. A growing body of evidence indicates that cell-based strategies might have promising therapeutic potentials for cardiac revascularization and the restoration of cardiac function. In that respect, several recent experimental studies have demonstrated varying degrees of cardiac regeneration using different stem cell populations such as embryonic stem cells, skeletal myoblasts, hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells [1, 2] . Similarly, our group has detected cardiac regeneration by cells of noncardiac origin in biopsies from the hearts of male patients that had undergone sex-mismatched cardiac transplantation [3] . Furthermore, first data from nonrandomized phase I clinical trials for treatment of acute myocardial infarction or chronic ischemic heart failure have emerged, the majority of which show improvements of clinical symptoms, left-ventricular function, and myocardial perfusion following transplantation of total bone marrow cells, bonemarrow-derived mononuclear cells, or peripheral bloodderived stem cells [1, 2] . However, there is an ongoing controversy about the cellular source with the highest potential for cardiovascular regeneration.
The report by Ma et al. [4] in the current issue of Cardiovascular Research provides encouraging new evidence concerning an alternative cellular source for cardiac repair following myocardial infarction. The authors transplanted human umbilical cord blood mononuclear cells containing 0.11 to 1.1% CD34-positive cells intravenously into immunoincompetent NOD/SCID mice that had or had not previously undergone ligation of the left anterior descending coronary artery. At time points 24 h, 1 and 3 weeks, homing to bone marrow, spleen, liver, and heart was analyzed by immunostaining, and myocardial scar formation, capillary density, and stromal-derived factor-1 (SDF-1) expression were assessed. Transplanted human umbilical cord blood cells were found in bone marrow, spleen, and liver of both control animals and mice with myocardial infarction. In contrast to controls however, transplanted cells were only detected in hearts of mice with myocardial infarction (10 out of 19 cases). The hearts of these animals were characterized by a reduction in infarct size and collagen deposition, while capillary density in the infarct border zone and SDF-1 expression were increased. These results indicate that human umbilical cord blood mononuclear cells have the potential to selectively home to the heart under ischemic conditions, and may contribute to regeneration of infarcted myocardium by enhancing neoangiogenesis and cardiac remodelling.
This finding is of particular interest, as the number of stem cells detected in different compartments of the body is very low, and the use of cells from cord blood might offer a number of advantages compared to other cellular sources for cardiovascular regeneration. In that respect, the number of stem cells that can be derived from human cord blood seems to be much higher than from peripheral blood, and at least equal to or higher than from bone marrow [5] . Furthermore, cord blood contains different subpopulations of stem cells, including endothelial progenitor cells and mesenchymal stem cells [6] . Cord bloodderived stem cells possess a high potential for transdifferentiation into a variety of cell types, and seem to proliferate and differentiate at a faster rate than stem cells derived from other adult sources, possibly due to their neonatal origin [7, 8] . From a functional perspective, transplanted umbilical cord blood CD34-positive stem cells have been shown to increase both neovascularization and perfusion in the ischemic hindlimb model [8] , where umbilical cord blood-derived stem cells have been shown to exhibit myoendothelial differentiation [9] . Moreover, ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors have been shown to home to the angiogenic tumour vasculature [10] .
Positive results from experimental and clinical studies have raised hopes that cell-based strategies for cardiovascular regeneration will be of therapeutic value in the future [1, 2] . However, there are still several unanswered questions that need to be addressed. First, studies comparing the different cellular sources for cardiac repair are warranted. These studies should determine the cell type or mixture of stem cell subpopulations with the highest regenerative capacity, the optimal number of cells to be transplanted, and the most efficacious route of delivery (i.e., intravenously, intracoronary, transendothelial, or intramyocardial). Similarly, as Ma et al. [4] have provided evidence for the cardiovascular repair potential of transplanted human cord blood cells, these will have to be subfractionated in future studies to characterize the functionally relevant stem cell or stem cell mixture. Secondly, the mechanisms of homing of the administered cells to the infarcted area of the myocardium need to be characterized (Fig. 1A) . What are the chemokines, chemokine receptors, endothelial adhesion molecules, and cellular integrins involved? In that respect, it is particularly interesting that Ma et al. [4] found a sevenfold upregulation of SDF-1 mRNA in the infarcts as compared to control. One could speculate that increased secretion of SDF-1 by the infarcted myocardium attracts circulating stem cells via the CXCR4 receptor, leading to activation of surface integrins and subsequent recruitment into the vasculature. Third, the mechanisms of action of transplanted stem cells need to be dissected (Fig.  1B) . As only low numbers of administered stem cells are found within the area of damage but are sufficient to exert beneficial effects, do they act indirectly via secretion of cytokines or directly by transdifferentiation into various functionally active cell types? Interestingly, Ma et al. [4] did not observe any evidence for cardiomyocyte differentiation of transplanted cord blood cells. However, Ma et al. [4] did not analyze myocardial and peripheral blood cytokine profiles in recipient mice, and also failed to provide data on the functional consequences of cord blood cell transplantation such as left-ventricular ejection fraction. Possibly, a strategy combining cardiac cell therapy and therapeutic neoangiogenesis using angiogenic growth factors might yield the best results for cardiovascular regeneration [11] . Interestingly, our group has recently shown that physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis [12] . Finally, largescale, placebo-controlled, randomized clinical trials need to be performed to confirm results from early phase I clinical trials. While the report by Ma et al. [4] provides encouraging new evidence for an alternative cellular source for cardiac repair, there clearly is still a long way to go before such cellbased therapeutic strategies can be translated into the clinics.
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